Clinical Trials Logo

Corneal Endothelial Dystrophy clinical trials

View clinical trials related to Corneal Endothelial Dystrophy.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT05136443 Completed - Corneal Edema Clinical Trials

Loteprednol Etabonate 0.25% for Prevention of Cornea Transplant Rejection

Start date: November 23, 2021
Phase: Phase 4
Study type: Interventional

The purpose of this study is to assess off-label use of loteprednol etabonate 0.25% ophthalmic suspension (Eysuvis) for prevention of immunologic rejection in the first year after Descemet membrane endothelial keratoplasty (DMEK). Topical corticosteroids have long been the mainstay for preventing and treating cornea transplant rejection although none are specifically approved for this purpose. The rates of immunologic rejection episodes and steroid-induced ocular hypertension will be compared with the respective rates observed in earlier studies with prednisolone acetate 1% suspension, loteprednol etabonate 0.5% gel, and fluorometholone 0.1% suspension after DMEK.

NCT ID: NCT04812067 Completed - Clinical trials for Corneal Endothelial Dystrophy

A Safety and Efficacy Trial of TTHX1114 in People With CED

OPTIC
Start date: November 30, 2021
Phase: Phase 2
Study type: Interventional

Expanded access, open label study at a single dose level in patients with CED that in the opinion of the investigators might benefit from TTHX1114

NCT ID: NCT04520321 Completed - Clinical trials for Endothelial Dysfunction

A Phase 1/ Phase 2 Study of TTHX1114(NM141)

INTREPID
Start date: August 19, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

Prospective, multicenter, randomized, masked, vehicle-controlled, dose-escalation study